Quinazoline analog HMJ-30 inhibits angiogenesis: Involvement of endothelial cell apoptosis through ROS-JNK-mediated death receptor 5 signaling

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 597-606

  Lu, Chi Cheng ^a   Chen, Hao Ping ^b   Chiang, Jo Hua ^c   Jin, Yi An ^d   Kuo, Sheng Chu ^e   Wu, Tian Shung ^c   Hour, Mann Jen ^e   Yang, Jai Sing ^e   Chiu, Yu Jen ^f  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Apoptosis; HMJ 30; HUVECs; MAPK JNK signal; ROS

Indexed keywords

6 FLUORO 2 (3 FLUOROPHENYL) 4 (CYANOANILINO) QUINAZOLINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; QUINAZOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; 6-FLUORO-2-(3-FLUOROPHENYL)-4-(CYANOANILINO)QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; DNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL DISRUPTION; CELL MIGRATION; CELL VIABILITY; CHICKEN; CHORIOALLANTOIS; CONCENTRATION RESPONSE; DNA FRAGMENTATION; DRUG EFFECT; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR RING; ANIMAL; AORTA; CELL CULTURE; CELL MOTION; CHICK EMBRYO; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTHRACENES; AORTA; APOPTOSIS; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; DNA; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903182147     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3250     Document Type: Article

References (47)

1. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002. (Pubitemid 37328908)
2. Tian T, Nan KJ, Wang SH, et al: PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 31: 1211-1219, 2010.
3. Hasan J, Shnyder SD, Bibby M, Double JA, Bicknel R and Jayson GC: Quantitative angiogenesis assays in vivo - a review. Angiogenesis 7: 1-16, 2004. (Pubitemid 39127766)
4. Stoletov K, Kato H, Zardouzian E, et al: Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 123: 2332-2341, 2010.
5. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
6. Xuan H, Zhao J, Miao J, Li Y, Chu Y and Hu F: Effect of Brazilian propolis on human umbilical vein endothelial cell apoptosis. Food Chem Toxicol 49: 78-85, 2011.
7. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 13: 159-167, 2003.
8. Plate KH, Breier G, Weich HA, Mennel HD and Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994. (Pubitemid 24357278)
9. Strickler JH and Hurwitz HI: Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17: 513-524, 2012.
10. Sandler AB, Johnson DH and Herbst RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10: 4258s-4262s, 2004. (Pubitemid 38812458)
11. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003. (Pubitemid 36910021)
12. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004. (Pubitemid 38618122)
13. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT and Wen PY: Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 12: 603-607, 2010.
14. Gild ML, Bullock M, Robinson BG and Clifton-Bligh R: Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 7: 617-624, 2011.
15. Bottsford-Miller JN, Coleman RL and Sood AK: Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30: 4026-4034, 2012.
16. Trowe T, Boukouvala S, Calkins K, et al: EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14: 2465-2475, 2008. (Pubitemid 351551082)
17. Raghav N and Singh M: Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H. Eur J Pharm Sci 54: 28-39, 2014.
18. Bilbro J, Mart M and Kyprianou N: Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res 33: 4695-4700, 2013.
19. Xu L and Russu WA: Molecular docking and synthesis of novel quinazoline analogues as inhibitors of transcription factors NF-êB activation and their anti-cancer activities. Bioorg Med Chem 21: 540-546, 2013.
20. Chatterjee N, Das S, Bose D, et al: Exploring the anti-inflammatory activity of a novel 2-phenylquinazoline analog with protection against inflammatory injury. Toxicol Appl Pharmacol 264: 182-191, 2012.
21. Hour MJ, Huang LJ, Kuo SC, et al: 6-Alkylamino- and 2,3-dihydro-3'- methoxy-2-phenyl-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem 43: 4479-4487, 2000.
22. Chiu YJ, Hour MJ, Lu CC, et al: Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res 29: 1448-1456, 2011.
23. Ren T, Qing Y, Dai N, et al: Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci 105: 186-194, 2014.
24. Wu PP, Liu KC, Huang WW, et al: Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. Oncol Rep 25: 551-557, 2011.
25. Yang JS, Hour MJ, Huang WW, Lin KL, Kuo SC and Chung JG: MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells. J Pharmacol Exp Ther 334: 477-488, 2010.
26. Pan SL, Guh JH, Peng CY, et al: YC-1 [3-(5′-hydroxymethyl-2'-furyl) -1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 314: 35-42, 2005.
27. Chiang JH, Yang JS, Lu CC, et al: Newly synthesized quinazolinone HMJ-38 suppresses angiogenetic responses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/death receptor signaling. Toxicol Appl Pharmacol 269: 150-162, 2013.
28. Kiriakidis S, Hogemeier O, Starcke S, et al: Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. Br J Nutr 93: 317-323, 2005.
29. Pyun BJ, Choi S, Lee Y, et al: Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res 68: 227-235, 2008. (Pubitemid 351380124)
30. Pang X, Yi Z, Zhang X, et al: Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69: 5893-5900, 2009.
31. Pang X, Yi Z, Zhang J, et al: Celastrol suppresses angiogenesis- mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70: 1951-1959, 2010.
32. Chung JG, Yang JS, Huang LJ, et al: Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 7: 3305-3317, 2007.
33. Huang WW, Chiu YJ, Fan MJ, et al: Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res 54: 1585-1595, 2010.
34. Lu CC, Yang JS, Chiang JH, et al: Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice. PLoS One 7: e36831, 2012.
35. Yodkeeree S, Sung B, Limtrakul P and Aggarwal BB: Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res 69: 6581-6589, 2009.
36. Prasad S, Yadav VR, Ravindran J and Aggarwal BB: ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res 71: 538-549, 2011.
37. Aggarwal BB, Bhardwaj U and Takada Y: Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 67: 453-483, 2004. (Pubitemid 39753674)
38. Iwai A, Shiozaki T and Miyazaki T: Relevance of signaling molecules for apoptosis induction on influenza A virus replication. Biochem Biophys Res Commun 441: 531-537, 2013.
39. Kannaiyan R, Shanmugam MK and Sethi G: Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303: 9-20, 2011.
40. Chiang JH, Yang JS, Lu CC, et al: Effect of DNA damage response by quinazolinone analogue HMJ-38 on human umbilical vein endothelial cells: Evidence for γH2A.X and DNA-PK-dependent pathway. Hum Exp Toxicol 33: 590-601, 2014.
41. Yang JS, Hour MJ, Kuo SC, Huang LJ and Lee MR: Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 24: 1769-1778, 2004.
42. Lu CC, Yang JS, Chiang JH, et al: Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling. Anticancer Res 32: 2895-2903, 2012.
43. Tozer GM, Kanthou C and Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435, 2005. (Pubitemid 40791485)
44. Portt L, Norman G, Clapp C, Greenwood M and Greenwood MT: Anti-apoptosis and cell survival: a review. Biochim Biophys Acta 1813: 238-259, 2011.
45. Li JH, Kirkiles-Smith NC, McNiff JM and Pober JS: TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171: 1526-1533, 2003. (Pubitemid 36900088)
46. Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
47. Zou W, Liu X, Yue P, et al: c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 64: 7570-7578, 2004. (Pubitemid 39372102)